Biomarkers of cardiotoxicity in multiple myeloma

Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about the biomarkers of cardiotoxicity in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.

Share this video